Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma — Stella

Home/Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type/

View on ClinicalTrials.gov

Recruiting

Back to Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

United States

Ohio State University Comprehensive Cancer Center, Columbus, Ohio

Key details

Phase

Early testing

Sponsor

Lapo Alinari

Enrollment target

~18 participants

Started

March 2023

Primary completion

March 2028

Age range

18 Years and older

Last updated February 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.